| Autor: |
Vaseem M. Khatri, Mariella A. Mestres-Villanueva, Sreenija Yarlagadda, Ajay Doniparthi, David B. Smith, Justyn Y. Nakashima, John M. Bryant, Dekuang Zhao, Rituraj Upadhyay, Matthew N. Mills, Daniel E. Oliver, Hsiang-Hsuan Michael Yu, Joshua D. Palmer, Nicole O. Williams, Reshma L. Mahtani, Manmeet S. Ahluwalia, Hatem H. Soliman, Hyo S. Han, Aixa E. Soyano, Youngchul Kim, Rupesh Kotecha, Sasha J. Beyer, Kamran A. Ahmed |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2374-4677 |
| DOI: |
10.1038/s41523-024-00711-w |
| Popis: |
Abstract Trastuzumab-deruxtecan (T-DXd) has demonstrated intracranial efficacy; however, safety and efficacy data remains limited with stereotactic radiosurgery (SRS). A multi-institutional review was performed with HER2+ or HER2-low metastatic breast cancer treated with T-DXd and SRS for active brain metastases. We identified 215 lesions treated over 48 SRS courses in 34 patients. Median follow up from T-DXd initiation was 13.9 months. The cumulative incidence of symptomatic radiation necrosis at 24 months per lesion was 2.1% and per patient 11%. The 12-month LC was 97%. HER2-low was associated with worse distant intracranial control (DIC) (adjusted HR 2.5, 95% CI 1.1–5.6, p = 0.03) and worse systemic progression free survival (PFS) (HR 4.1, 95% CI 1.6–10.7, p = 0.004). Concurrent SRS and T-DXd has excellent local control, without an increased risk of radiation necrosis. HER2-low disease is associated with worse systemic PFS and DIC with T-DXd compared to HER2+. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink